(资料图片仅供参考)
5月29日北向资金减持500.0股德琪医药-B（06996.HK）。近5个交易日中，获南向资金减持的有5天，累计净减持22.35万股。近20个交易日中，获南向资金减持的有20天，累计净减持160.3万股。截至目前，南向资金持有德琪医药-B（06996.HK）2754.5万股，占公司已发行普通股的4.08%。
德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-30
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-29
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-28
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-27
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26
2023-05-26